Navigation Links
Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
Date:10/11/2007

PARIS, October 11 /PRNewswire-FirstCall/ --

(EUR millions) 2007 2006 07/06

%Sales %Sales %

change

Southern Europe (1) 20.63 70.6 17.61 70.7 17

Other EU countries (2) 7.07 24.2 6.06 24.4 17

Other markets 1.51 5.2 1.22 4.9 24

SLIT 22.13 75.8 18.14 72.9 22

SCIT 5.96 20.4 5.60 22.5 6

Other products 1.12 3.8 1.15 4.6 (3)

Total Q3 sales 29.21 100.0 24.89 100.0 17

Southern Europe (1) 77.16 74.2 65.71 73.8 17

Other EU countries (2) 22.83 21.9 19.78 22.2 15

Other markets 4.02 3.9 3.60 4.0 12

SLIT 81.88 78.7 67.55 75.8 21

SCIT 17.78 17.1 17.23 19.3 3

Other products 4.35 4.2 4.31 4.8 1

9-month cumulated sales 104.01 100.0 89.09 100.0 17

(1) Portugal, Spain, France, Italy, Greece;

(2) Switzerland included

Sales growth and financial position

2007 3rd quarter sales registered further significant growth in all markets (+17%, vs +9% in 2006). The most vigorous market segment remained sublingual route desensitization (SLIT, +22%). Subcutaneous route sales (SCIT) increased by 6%. Cumulative sales for the first nine months of the year increased by 17% (vs +13% in 2006).

The financial position improved. Net debt declined 40% from net debt at 30 September 2006.

Significant 3rd quarter transactions and events

The new allergen production facility has been completed. Collection and validation operations are being implemented within the planned timeframe.

The market authorisation procedure for the ORALAIR(R) Grasses allergen tablet by the P.E.I. German agency is still ongoing. Management is confident the procedure will soon be completed.

Outlook for the current year

The Group now provides guidance of 12% to 14% full-year sales growth and profitability close to that of 2006 in absolute value.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma.

A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes more than 15% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

With a registered office in France, Stallergenes markets its products in approximately 40 countries. Stallergenes realised 2006 sales of EUR 126.5 million, of which half outside France.

Stallergenes' shares are listed on Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP

For additional information on Stallergenes, please visit our website: http://finance.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Midwest life science stocks sizzle in a tepid first quarter
2. CIOs looking to hire more IT workers in second quarter
3. Fiserv posts 30 percent quarterly loss
4. Sonic Foundry reports first cash-positive quarter
5. Venture capital above $6B for third straight quarter
6. Third Wave reports $5.2M third quarter loss
7. Inventions could fall prey to Monday morning quarterbacking
8. Merge fails to file quarterly financial report
9. Rexnord to slash debt after quarterly loss
10. Johnson Controls reports record quarterly sales
11. Sonic Foundry reports quarterly loss, higher Mediasite sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):